Vaxcyte's pneumococcal vaccine VAX-31 met all Phase III trial goals, prompting the San Carlos company to launch $1 billion in public offerings.

An East Bay life sciences campus goes for a deep discount as the sector struggles with vacancies.

This Nobel Prize winner's startup could be the Bay Area's ninth life sciences IPO this year.

Shares of San Carlos-based Vaxcyte (Nasdaq: PCVX) surged nearly 30% Monday after late-stage trial results signaled its lead vaccine candidate could steal significant share from Pfizer and Merck.

In a test of investors' appetite, Lilly-connected TRex Bio plots a $153 million IPO.

Meet the Bay Area's latest Nobel Prize winner

After a scary collapse at a playoff game, Valkyries' head coach looks to a San Francisco company's signature product for support.

A $1.6 billion rebuild of UCSF Benioff Children's Hospital Oakland is uncovering its past and future.

Why this biotech sees a small bump up in funding as a big deal.

Its drug was rejected twice by regulators, but now this company is trying again.

Here's what you get when you mix AI, 3 ex-Genentech employees, a knotty health care system and a half-billion dollars

'The inefficiency is kind of the magic of it': How a UCSF scientist's persistence led to Revolution Medicines' groundbreaking pancreatic cancer drug and a $1 million prize.

Bay Area companies have scored 14 drug approvals from the FDA this year. Find out who got the latest one.

Could this drug for 'stone man' syndrome win the 14th FDA approval for Bay Area companies this year?

Here's how this AI-focused company — one of the first with a biotech drug in the clinic — plans to use its fresh $75M round

ALS is devastating. This startup thinks it's found a way to strike it out

Here's why this East Bay giant is getting blasted by an activist investor.

TRex Bio Inc. plans to become the Bay Area's eighth life sciences IPO this year.

After raising $350 million in an IPO, the Electra Therapeutics CEO told the Business Times the process "really does test the cohesiveness of the team."

Ultragenyx's $4 million gene therapy wins FDA approval for a rare brain and nervous system disorder

Reverse merger, $225 million funding push young Peninsula company public

Dualitas Therapeutics secures $36.5 million upfront from Roche to develop bispecific antibodies for immunology and inflammatory diseases.

After layoffs, cell therapy manufacturer Cellares has inked a new deal. The CEO says, "The strategy hasn't changed, the fundamentals also have not changed."

This onetime Gilead exec has big IPO plans for her South San Francisco startup.

Lenders are taking over biotech projects from developers amid a continued weak market.

GV, SoftBank and others pumped $275 million into this startup. Find out where it will spend the money.

This company's stock took a hit just 10 months after its IPO. Here’s why shares tanked — and how the company plans to push forward.

Sleepy dogs, problem bleeds and Michael J. Fox's foundation land Lasker awards, a prize known as the “American Nobels.”

The Bay Area's biotech sector has struggled in recent years, but a summer revival could signal brighter days ahead.

Franklin unit rebuilds after 9/11 tragedy

Ultragenyx vows 'significant' cuts after experimental rare-disease drug fails late-stage clinical trial

One of the Bay Area's most storied biotech companies plans a massive new R&D center to kick off the reimagining of its Peninsula headquarters.

Google left Pacific Shores behind. Now one of the Bay Area's fastest-growing biotech companies is poised to take it over in a major move.

Fast-growing biotech manufacturer loses major customer, plans layoffs

Off the clock: How Ultragenyx's new $2.7 million therapy targets patients with a rare genetic disease

BioMarin Pharmaceuticals is paying $275 million upfront for a Dutch company's experimental drug that could become the first pill-based treatment for a rare genetic bone disease that currently requires...

Sean Parker's San Francisco-based institute has a vision for tackling cancer. This company is taking a big step toward it.

Lilly's bankruptcy court deal for Sangamo's gene therapy technologies faces questions from Alexion, Astellas and Genentech

Heart attack: A Bay Area company is suing giant Bristol-Myers Squibb to protect an important cardiac drug.

Here are the two big winners for bankrupt Sangamo Therapeutics' assets.

Many startups raise seed money from VCs and don't go on to get any more investment. Here's how one Alameda company beat the odds.

Amber Salzman has seen a rare, inherited muscle disorder devastate her family. Now, with a fresh $90 million supply of cash, her South San Francisco company is closer to doing something about it.

ReCode Therapeutics CEO exits for chairman role as it brings in new money, new direction

'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of cutting-edge pancreatic cancer drug

Wearables maker Oura Health bought its San Francisco headquarters at 500 Pine St. for $41.5 million after signing a full-building lease earlier this year. Here’s why owner-users are snapping up proper...

Here's how much lawyers will earn from suits around 23andMe's 2023 data breach.

Braveheart Bio raised $382.5M in its IPO, pricing shares at $18. The San Francisco biotech is developing a drug for hypertrophic cardiomyopathy.